Calcineurin inhibitor and mTOR inhibitor combination

This page covers all Calcineurin inhibitor and mTOR inhibitor combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Calcineurin (tacrolimus) and mTOR (sirolimus), Calcineurin (tacrolimus) and mTOR (everolimus).

Targets

Calcineurin (tacrolimus) and mTOR (sirolimus) · Calcineurin (tacrolimus) and mTOR (everolimus)

Marketed (3)

• Tacrolimus/Sirolimus · University of Miami · Immunology / Transplantation
  Tacrolimus and sirolimus are immunosuppressive agents that inhibit T-cell activation and proliferation through different pathways to prevent organ rejection.
• Tacrolimus and Everolimus · Chang Gung Memorial Hospital · Immunology / Transplantation
  Tacrolimus and everolimus are immunosuppressive agents that inhibit mTOR and calcineurin pathways to prevent T-cell activation and proliferation.
• Tacrolimus and Sirolimus · Foundation for Liver Research · Immunology / Transplantation
  Tacrolimus and sirolimus are immunosuppressive agents that inhibit T-cell activation and proliferation through different pathways to prevent organ rejection.

Patent intelligence

• calcineurin inhibitor and mtor inhibitor combination patent landscape — aggregated cliff calendar, attackable patents, originator estates